Perioperative chemotherapy with and without high-dose methotrexate in adult osteosarcoma
Authors:
- Marcelo Vailati NegrãoMNMarcelo Vailati Negrão
- Lucila S. da Silva RochaLRLucila S. da Silva Rocha
- Daniel da Motta GirardiDGDaniel da Motta Girardi
- Olavo FeherOFOlavo Feher
- 1 September 2017
- journal article
- Published by Wolters Kluwer Health in Anti-Cancer Drugs
- Vol. 28 (8) , 915-921
Abstract
Treatment of adult osteosarcoma (AOS) includes perioperative chemotherapy and surgery. Standard chemotherapy consists of cisplatin (CP) and doxorubicin (DOX). Although considered the standard of care for pediatric patients, high-dose methotrexate (HDM) remains controversial in adults. We aimed to evaluate the role of HDM in AOS treated with curative intent. This study included patients with AOS who received perioperative chemotherapy with DOX and CP (group 1; N=16) and DOX, CP, and HDM (group 2; N=10). The primary endpoint was grade 3 or superior toxicities. The secondary endpoints included overall survival (OS) and disease-free survival. Despite lower average age (35.0±12.1 vs. 18.9±2.1 years), group 2 presented more grade 3–4 thrombocytopenia (0 vs. 15.8%) and mucositis (0 vs. 21.1%), whereas group 1 presented more grade 3–4 neutropenia (46.6 vs. 26.3%). No grade 3–4 renal toxicities occurred. Two grade 5 toxicities occurred in group 2, both after the first HDM cycle. Disease-free survival (4.38±0.61 vs. 2.3±0.54 years, P=0.228) and OS (4.70±0.56 vs 2.52±0.57 years, P=0.107) were not statistically different, but presented a trend toward better outcomes in group 1. The 4-year OS was 65.6 and 32.8% for groups 1 and 2, respectively. HDM was associated with greater severe and lethal toxicity when added to CP and DOX in AOS. In addition, it does not seem to impact on treatment efficacy. These data do not support the use of HDM for the perioperative treatment of AOS.Keywords
This publication has 25 references indexed in Scilit:
- Long‐term results (>25 years) of a randomized, prospective clinical trial evaluating chemotherapy in patients with high‐grade, operable osteosarcomaCancer, 2012
- A retrospective safety analysis of adult patients treated with high-dose methotrexate for osteosarcoma in Stockholm, Sweden.Journal of Clinical Oncology, 2012
- Frontline treatment of localized osteosarcoma without methotrexateCancer, 2011
- Osteosarcoma incidence and survival rates from 1973 to 2004Cancer, 2009
- Management of osteosarcomaCurrent Treatment Options in Oncology, 2006
- Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma IntergroupThe Lancet, 1997
- A comparison of two short intensive adjuvant chemotherapy regimens in operable osteosarcoma of limbs in children and young adults: the first study of the European Osteosarcoma Intergroup.Journal of Clinical Oncology, 1992
- Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience.Journal of Clinical Oncology, 1992
- Treatment of osteosarcoma of the extremities with the T-10 protocol, with emphasis on the effects of preoperative chemotherapy with single-agent high-dose methotrexate: a Scandinavian Sarcoma Group study.Journal of Clinical Oncology, 1991
- Adjuvant chemotherapy for osteosarcoma: a randomized prospective trial.Journal of Clinical Oncology, 1987